Patents by Inventor Bernard L. Hirschbein

Bernard L. Hirschbein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140256743
    Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Application
    Filed: May 20, 2014
    Publication date: September 11, 2014
    Applicants: Merck Frosst Canada Ltd., Axys Pharmaceuticals, Inc.
    Inventors: Christopher I. Bayly, Cameron Black, Serge Leger, Chun Sing Li, Dan McKay, Christophe Mellon, Jacques Yves Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien, Michael J. Green, Bernard L. Hirschbein, James William Janc, James T. Palmer, Chitra I. Baskaran
  • Patent number: 8772336
    Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: July 8, 2014
    Assignees: Merck Frosst Canada Ltd., Axys Pharmaceuticals, Inc.
    Inventors: Christopher I. Bayly, Cameron Black, Serge Leger, Chun Sing Li, Dan McKay, Christophe Mellon, Jacques Yves Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien, Michael J. Green, Bernard L. Hirschbein, James William Janc, James T. Palmer, Chitra I. Baskaran
  • Patent number: 8318748
    Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: November 27, 2012
    Assignees: Merck, Sharp & Dohme Corp., Axys Pharmaceuticals, Inc.
    Inventors: Christopher I. Bayly, Cameron Black, Serge Leger, Chun Sing Li, Dan McKay, Christophe Mellon, Jacques Yves Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien, Michael J. Green, Bernard L. Hirschbein, James William Janc, James T. Palmer, Chitra Baskaran
  • Publication number: 20110230446
    Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Application
    Filed: May 25, 2011
    Publication date: September 22, 2011
    Applicants: Axys Pharmaceuticals, Inc., Merck Canada Inc.
    Inventors: Christopher I. Bayly, Cameron Black, Serge Leger, Chun Sing Li, Dan McKay, Chirstophe Mellon, Jacques Yves Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien, Michael J. Green, Bernard L. Hirschbein, James William Janc, James T. Palmer, Chitra Baskaran
  • Patent number: 7973037
    Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Grant
    Filed: April 8, 2008
    Date of Patent: July 5, 2011
    Assignees: Axys Pharmaceuticals, Inc., Merck Canada Inc.
    Inventors: Christopher I. Bayly, Cameron Black, Serge Leger, Chun Sing Li, Dan McKay, Christophe Mellon, Jacques Yves Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien, Michael J. Green, Bernard L. Hirschbein, James William Janc, James T. Palmer, Chitra Baskaran
  • Publication number: 20080188529
    Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Application
    Filed: April 8, 2008
    Publication date: August 7, 2008
    Inventors: Christopher I. Bayly, Cameron Black, Serge Leger, Chun Sing Li, Dan McKay, Christophe Mellon, Jacques Yves Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien, Michael J. Green, Bernard L. Hirschbein, James William Janc, James T. Palmer, Chitra Baskaran
  • Publication number: 20030232863
    Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Application
    Filed: February 28, 2003
    Publication date: December 18, 2003
    Inventors: Christopher I. Bayly, Cameron Black, Serge Leger, Chun Sing Li, Dan McKay, Christophe Mellon, Jacques Yves Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien, Michael J. Green, Bernard L. Hirschbein, James William Janc, James T. Palmer, Chitra Baskaran
  • Patent number: 5859233
    Abstract: The invention provides a method of synthesizing oligonucleotide N3'.fwdarw.P5' phosphoramidates using an amine-exchange reaction of phosphoramidites in which a -deprotected 3'-amino group of a solid phase supported oligonucleotide chain is exhanged for the amino portion of a 5'-phosphoramidite of an incoming monomer which has a protected 3'-amino group. The resulting internucleotide phosphoramidite linkage is then oxidized to form a stable protected phosphoramidate linkage. The method of the invention greatly improves product yields and reduces reagent usage over currently available methods for synthesizing the above class of compound.
    Type: Grant
    Filed: December 20, 1996
    Date of Patent: January 12, 1999
    Assignee: Lynx Therapeutics, Inc.
    Inventors: Bernard L. Hirschbein, Karen L. Fearon, Sergei M. Gryaznov, Sarah N. McCurdy, Jeffrey S. Nelson, Ronald G. Schultz
  • Patent number: 5824793
    Abstract: The invention provides a method of synthesizing oligonucleotide N3'.fwdarw.P5' phosphoramidates using an amine-exchange reaction of phosphoramidites in which a deprotected 3'-amino group of a solid phase supported oligonucleotide chain is exhanged for the amino portion of a 5'-phosphoramidite of an incoming monomer which has a protected 3'-amino group. The resulting internucleotide phosphoramidite linkage is then oxidized to form a stable protected phosphoramidate linkage. The method of the invention greatly improves product yields and reduces reagent usage over currently available methods for synthesizing the above class of compound.
    Type: Grant
    Filed: June 14, 1996
    Date of Patent: October 20, 1998
    Assignee: Lynx Therapeutics, Inc.
    Inventors: Bernard L. Hirschbein, Karen L. Fearon, Sergei M. Gryaznov, Sarah N. McCurdy, Jeffery S. Nelson, Ronald G. Schultz
  • Patent number: 5342816
    Abstract: An imaging medium capable of being imaged to form a transparency comprises a substantially transparent support having a thickness of at least about 20 .mu.m, a color-forming layer superposed on the support and comprising a color-forming composition adapted to undergo a change of color upon increase in the temperature of the color-forming layer above a color-forming temperature for a color-forming time; and a bubble-suppressant layer superposed on the color-forming layer and having a thickness of at least about 10 .mu.m. Upon imagewise increase in the temperature of the color-forming layer above the color-forming temperature for the color-forming time, in heated regions the color-forming layer undergoes its change of color but remains essentially free from bubbles, thereby providing an image in which the colored regions are not blackened when viewed in transmission.
    Type: Grant
    Filed: August 18, 1993
    Date of Patent: August 30, 1994
    Assignee: Polaroid Corporation
    Inventors: Edward P. Lindholm, Stephen J. Telfer, Michael J. Zuraw, Bernard L. Hirschbein
  • Patent number: 5292875
    Abstract: A method for synthesizing sulfurized oligonucleotide analogs, such as phosphorothioate and phosphorodithioate analogs, is provided that employs a thiophosphorus compound, such as a thiophosphoric, dithiophosphoric, thiophosphinic, or dithiophosphinic acid disulfide or polysulfide, as a sulfurizing agent. The method of the invention may be used to sulfurize any phosphorous(III)containing intermediate. Preferably, the method is practiced on a commercial DNA synthesizer using phosophoramidite and/or phosphorthioamidite intermediates.
    Type: Grant
    Filed: August 27, 1993
    Date of Patent: March 8, 1994
    Assignee: Lynx Therapeutics, Inc.
    Inventors: Wojciech J. Stec, Bogdan Uznanski, B. John Bergot, Bernard L. Hirschbein, Karen L. Fearson
  • Patent number: 5166387
    Abstract: A method for synthesizing sulfurized oligonucleotide analogs, such as phosphorothioate and phosphorodithioate analogs, is provided that employs a thiuram disulfide as a sulfurizing agent. The method of the invention may be used to sulfurize any phosphorous(III)-containing intermediate. Preferably, the method is practiced on a commercial DNA synthesizer using phosphoramidite and/or phosphorthioamidite intermediates.
    Type: Grant
    Filed: January 12, 1990
    Date of Patent: November 24, 1992
    Assignee: Applied Biosystems, Inc.
    Inventor: Bernard L. Hirschbein
  • Patent number: 5151510
    Abstract: A method for synthesizing sulfurized oligonucleotide analogs, such as phosphorothioate and phosphorodithioate analogs, is provided that employs a thiophosphorus compound, such as a thiophosphoric, dithiophosphoric, thiophosphinic, or dithiophosphinic acid disulfide or polysulfide, as a sulfurizing agent. The method of the invention may be used to sulfurize any phosphorous(III)-containing intermediate. Preferably, the method is practiced on a commercial DNA synthesizer using phosphoramidite and/or phosphorthioamidite intermediates.
    Type: Grant
    Filed: April 20, 1990
    Date of Patent: September 29, 1992
    Assignee: Applied Biosystems, Inc.
    Inventors: Wojciech J. Stec, Bogdan Uznanski, B. John Bergot, Bernard L. Hirschbein, Karen L. Fearon
  • Patent number: 4478762
    Abstract: The potassium salt of phosphoenolpyruvic acid (PEP-K), used as a phosphorylation agent particularly in enzymatic reactions, is prepared by a process which consists of two steps, namely the treatment of a halopyruvic acid with a trialkyl phosphite and the hydrolysis of the dialkyl phosphate of enolpyruvic acid thus formed in an aqueous medium and in the presence of potassium hydroxide.
    Type: Grant
    Filed: March 30, 1982
    Date of Patent: October 23, 1984
    Assignee: Massachusetts Institute of Technology
    Inventors: George M. Whitesides, Bernard L. Hirschbein, Francois P. Mazenod